Skip to main content
New GLP-1 protocol guide just published Read →
Clinician hands drawing peptide solution into a syringe
§ 05 The Workshop

Tools for the
working hand.

Practical, single-purpose calculators for anyone handling research peptides — dose math, reconstitution steps, compound matching, and regulatory lookup. Each one is its own workspace.

4
Tools available
2
Live calculators
2
Reference trackers
§ 01 Dose Calculator

Find the exact volume.

Calculate injection volume from vial size, concentration, and target dose. Accounts for TFA contamination and purity.

mg
mL
%
TFA removed
Counterion exchanged — vial weight ≈ peptide weight
Results
0.102 mL
Injection volume
10.2 IU
100-unit syringe
2450
mcg / mL
19.6 doses
Per vial

Disclaimer  ·  This calculator is for educational purposes only. These calculations do not constitute medical advice. Verify all calculations before use. Research peptides are not approved for human administration.

§ 02 Reconstitution Guide

Mix it cleanly.

Interactive step-by-step protocol for reconstituting lyophilized peptides safely with bacteriostatic water.

5.00
mL water to add
500
100-unit IU
1
mg / mL final
Protocol
0 of 8 done

Disclaimer  ·  For educational purposes only. Research peptides are not FDA-approved for human use. Consult a physician before use.

§ 03 Peptide Finder

Match goal to molecule.

Filter compounds by health goal, evidence level, and administration route to narrow the field before you dive into profiles.

§ 01 Goals (choose all that apply)
§ 02 Evidence preference
§ 03 Route preference
18 matches
Semaglutide FDA Approved

“FDA approved for obesity — strongest weight loss evidence (14.9% STEP-1)”

Tirzepatide FDA Approved

“Largest weight loss in any Phase 3 trial (22.5% SURMOUNT-1)”

Liraglutide FDA Approved

“FDA approved; longest established GLP-1 safety record”

PT-141 FDA Approved

“FDA approved (Vyleesi) — only approved peptide for sexual dysfunction”

Oxytocin Off-Label

“Intranasal; social bonding, anxiety, potential sleep benefits”

Sermorelin Off-Label

“GHRH analog with human Phase I data; historically used in adult GH deficiency”

CJC-1295 Research Only

“GHRH analog; synergistic with Ipamorelin for GH release”

Ipamorelin Research Only

“Most selective GHSR agonist — minimal cortisol/prolactin spillover”

BPC-157 Research Only

“Strongest animal data for tendon/ligament repair; now 503A prohibited”

TB-500 Research Only

“RegeneRx Phase II cardiac data; actin-regulatory tissue repair mechanism”

Thymosin Alpha-1 Research Only

“Approved in 35+ countries; strongest clinical data of any research immune peptide”

GHK-Cu Research Only

“Decades of collagen and wound healing research; topical use well established”

Semax Research Only

“BDNF/NGF upregulation; Russian registration for stroke/cognitive decline”

Selank Research Only

“Anxiolytic without sedation/tolerance — GABAergic + BDNF mechanism”

MK-677 Research Only

“Oral GHSR agonist (~60–70% bioavailability) — convenience advantage”

Epitalon Research Only

“Telomerase activation claim; limited but interesting Khavinson research”

DSIP Research Only

“Direct delta wave sleep induction without GABA mechanism”

GHRP-2 Research Only

“Most potent GHSR agonist; Japan-approved for diagnostic use”

§ 04 Regulatory Status

Know the legal landscape.

FDA approval, compounding availability, and sports-governance classification for the major compounds.

Legend
FDA Approved
Off-Label
Research Only
503A Prohibited
Compound FDA
Semaglutide
FDA Approved
Yes — Ozempic, Wegovy, Rybelsus
Tirzepatide
FDA Approved
Yes — Mounjaro, Zepbound
Liraglutide
FDA Approved
Yes — Victoza, Saxenda
Bremelanotide (PT-141)
FDA Approved
Yes — Vyleesi (HSDD in women)
Sermorelin
Off-Label
Previously — Geref withdrawn 2008
Oxytocin
Off-Label
Yes — Pitocin (obstetric use)
BPC-157
503A Prohibited
No
CJC-1295
503A Prohibited
No
Ipamorelin
503A Prohibited
No
TB-500 (Thymosin β-4)
503A Prohibited
No
Thymosin Alpha-1
503A Prohibited
No (approved outside US)
Selank
Research Only
No
Semax
Research Only
No
GHK-Cu
Research Only
No (cosmetic use)
MK-677 (Ibutamoren)
Research Only
No (IND withdrawn)

Last reviewed  ·  August 2025. Regulatory status changes frequently. Verify current status with a licensed pharmacist or attorney. Full regulatory guide →